Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
biochaperone glucagon
- Development stage
- Phase 1
- Lead developer
- Adocia
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
BioChaperone glucagon is a ready-to-inject stable aqueous formulation of human glucagon developed by Adocia. It utilizes proprietary BioChaperone technology that forms complexes with glucagon to improve stability in aqueous solution, protecting against degradation and fibril formation. This formulation eliminates the need for reconstitution before use, making it potentially valuable for emergency treatment of severe hypoglycemia.
- Brand names
- BioChaperone Glucagon
- Other names
- BioChaperone human glucagonRecombinant human glucagon
02
Targets
GCGR (Glucagon receptor)
Beyond the preview
Go deeper on biochaperone glucagon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on biochaperone glucagon.